9
Jul2019

Reflections on the Advancing Ethical Research Conference

Tags:
9 Jul
No comments

PRIM&R’s 2018 Advancing Ethical Research Conference (AER18) was very inspiring. It provided me an opportunity to be immersed in an interesting learning opportunity, wherein I noted a common theme of this conference was to highlight the changes in the revised Common Rule and its practical implementation. Read more

8
Jul2019

Share your experience as an HRPP/IRB professional by July 12

Tags:
8 Jul
No comments

As the Certified IRB Professional (CIP®) program approaches its milestone twentieth year, PRIM&R and the CIP Council are undertaking a series of activities aimed at assessing the current eligibility guidelines and the content of the CIP exam against the tasks and responsibilities that those charged with HRPP/IRB administration perform. The first part of this process is a comprehensive job analysis survey, which aims to capture the range of responsibilities for which offices that oversee IRBs are accountable. Anyone involved with the management and administration of HRPP/IRBs is encouraged to participate in this important project before the survey closes on July 12. Read more

25
Jun2019

Record-Keeping and Data Security: Insights for IRB Administrators and Researchers

Tags:
25 Jun
No comments

Since the National Archives in Washington were founded they have solved historical mysteries, provided key information, and unlocked a great deal of forgotten knowledge. The power of records and record keeping is influential at all levels of human existence, but also may be harmful to the least empowered individuals in society (such as refugees or the elderly). At PRIM&R's AER Conference, presenters offered insights into essential documentation and stressed the importance of good record keeping and data management for IRBs. Read more

19
Jun2019

Transparently Unclear: Data Sharing in Machine Learning Research

Tags:
19 Jun
No comments

There’s a growing trend in Social, Behavioral, and Education Research (SBER)–machine learning–in which investigators often request to obtain, through direct interaction and intervention, various sets of data on human subjects, including their physiological (i.e., data obtained from either invasive or non-invasive means) and/or biometric data (e.g., audio/visual recordings). The research as originally conceived may or may not have been considered human subjects research, but its ultimate purpose is to teach machines how to think, draw conclusions, and process information in much the same way humans do. Read more

13
Jun2019

PRIM&R’s Response to FDA’s Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning-Based Software as a Medical Device

Tags:
13 Jun
No comments

In April, the Food and Drug Administration (FDA) issued a discussion paper, "Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD).” The paper represents FDA’s response to the growing number of medical device manufacturers who are utilizing artificial intelligence and machine learning technologies to continuously improve their products. On June 3, PRIM&R submitted comments in response to the discussion paper, thanking the FDA for their consideration of the public health implications of the use of these technologies, but also cautioning that any new regulatory approach in this area must address the protection of individuals whose personal information and data are being used in the creation and ongoing testing of these technologies. Read more

11
Jun2019

PRIM&R’s Response to FDA’s Draft Guidance on “Cancer Clinical Trial Eligibility Criteria: Minimum Age for Pediatric Patients”

Tags:
11 Jun
No comments

In March, the Food and Drug Administration (FDA) issued a guidance, "Cancer Clinical Trial Eligibility Criteria: Minimum Age for Pediatric Patients." The guidance is one of the latest moves by the agency to expand eligibility criteria, and hence the knowledge base for how drugs work in various populations, for the clinical trials they regulate. It makes recommendations not only for sponsors but also for IRBs. On May 13, PRIM&R submitted comments in response to the draft guidance. PRIM&R also has an upcoming webinar, Pediatric Risk Determination: IRB Considerations and Cases, on Thursday, September 19 that will review considerations for IRBs in assessing the risks and benefits of pediatric studies. Read more